Descriptive Analyses of Clinical Characteristics and Treatment Patterns of Breast Cancer Patients Initiating Palbociclib (Ibrance®) Treatment in the US Community Oncology Setting

Documents

Study protocol

Initial protocol

Ibrance EMR utilization study NI Study Protocol 03 December 2015 Final (Clean)

Study results

Study results

A5481067 Abstract

Study report

Other information

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Conflicts of interest of investigators

A5481067